Canakinumab for Pyoderma Gangrenosum

Sponsor
University of Zurich
Study ID
NCT01302795
Phase
PHASE2
Status
Completed

Conditions

  • Pyoderma Gangrenosum

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Canakinumab — DRUG
    Monoclonal antibody inhibiting interleukin 1 beta

Study Details

This study is a prospective open label evaluation of Canakinumab (Ilaris) for treatment of subjects with pyoderma gangrenosum.

Key Dates

Start date
Feb 28, 2011
Status verified
Sep 2016
Primary completion
Aug 31, 2014
Completion
Nov 30, 2015

Study Design

Enrollment
5 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Canakinumab
    Canakinumab s.c. 150-300mg Week 0, (2), 8

Primary Outcome Measure

Change of the Physician's global assessment (Grade 0-4) of the target lesion [ Time Frame: Week 2, 4, 8, 16 ]

Related Studies